keyword
MENU ▼
Read by QxMD icon Read
search

metronomic chemotherapy

keyword
https://www.readbyqxmd.com/read/29299975/castration-is-a-prerequisite-for-the-inhibitory-effect-of-metronomic-chemotherapy-on-the-growth-of-experimental-castration-resistant-prostate-cancer
#1
Åsa Jellvert, Daniel Åhs, Josefin Olausson, Ingela Franck Lissbrant, Jan-Erik Damber, Karin Welén
BACKGROUND: Low-dose metronomic chemotherapy (LDMC) is an alternative for treatment of patients with late-stage prostate cancer (PC) not susceptible to regular chemotherapy due to its severe side effects. The exact working mechanisms of LDMC have not been established, although anti-angiogenic effects have been identified. In PC, several studies show clinical effects from LDMC but the mode of action and the role of androgen signaling for its effect are not known. In this study, we used a xenograft model to evaluate the effect of LDMC on PC growth in relation to androgen deprivation...
January 4, 2018: Acta Oncologica
https://www.readbyqxmd.com/read/29298280/complete-objective-response-stable-for-5-years-with-the-di-bella-method-of-multiple-metastatic-carcinoma-of-the-breast
#2
Giuseppe Di Bella, Biagio Colori, Rosilde Toscano
Breast cancer is the most common cancer and the leading cause of cancer death among women. Despite all efforts, about 11,939 deaths and 50,000 new diagnoses for breast cancer were estimated among Italian women in 2016. Therefore new approaches are needed to improve the survival and higher remission rates. We present a case of a woman with carcinoma of the breast and multiple metastases after right mastectomy, axillary dissection, repeated cycles of chemo and radiotherapy, and estrogen block. Biological method formulated by Prof...
December 4, 2017: Neuro Endocrinology Letters
https://www.readbyqxmd.com/read/29291168/metronomic-chemotherapy-for-non-metastatic-triple-negative-breast-cancer-selection-is-the-key
#3
REVIEW
Connie Rabanal, Rossana Ruiz, Silvia Neciosup, Henry Gomez
Triple negative breast cancer (TNBC) accounts for 15%-20% of all breast cancer, and is still defined as what it is not. Currently, TNBC is the only type of breast cancer for which there are no approved targeted therapies and maximum tolerated dose chemotherapy with taxanes and anthracycline-containing regimens is still the standard of care in both the neoadjuvant and adjuvant settings. In the last years, metronomic chemotherapy (MC) is being explored as an alternative to improve outcomes in TNBC. In the neoadjuvant setting, purely metronomic and hybrid approaches have been developed with the objective of increasing complete pathologic response (pCR) and prolonging disease free survival...
December 10, 2017: World Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29285388/metronomic-cyclophosphamide-induced-long-term-remission-after-recurrent-high-grade-serous-ovarian-cancer-a-case-study
#4
Leonora Wijnandina de Boo, Annelie Johanna Elisabeth Vulink, Monique Elisabeth Martina Maria Bos
Metronomic oral cyclophosphamide has gained increasing interest in recent years as a promising maintenance therapy in advanced, platinum-sensitive, high-grade serous ovarian cancer (HGSOC). Metronomic treatment with cyclophosphamide refers to the frequent, usually daily, administration of a low (oral) dose of cyclophosphamide with no prolonged drug-free breaks. Main advantages of this treatment are the effective reduction of tumour activity, oral administration in an outpatient setting, low cost and the low toxicity profile...
December 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29221287/anti-cancer-activity-of-dose-fractioned-mpe-bevacizumab-regimen-is-paralleled-by-immune-modulation-in-advanced-squamous-nslc-patients
#5
Pierpaolo Pastina, Valerio Nardone, Stefania Croci, Giuseppe Battaglia, Francesca Vanni, Cristiana Bellan, Marcella Barbarino, Veronica Ricci, Susan Costantini, Francesca Capone, Cirino Botta, Mayra Rachele Zarone, Gabriella Misso, Mariarosaria Boccellino, Michele Caraglia, Antonio Giordano, Piero Paladini, Pierfrancesco Tassone, Pierosandro Tagliaferri, Maria Grazia Cusi, Luigi Pirtoli, Pierpaolo Correale
Background: Results from the BEVA2007 trial, suggest that the metronomic chemotherapy regimen with dose-fractioned cisplatin and oral etoposide (mPE) +/- bevacizumab, a monoclonal antibody to the vascular endothelial growth factor (VEGF), shows anti-angiogenic and immunological effects and is a safe and active treatment for metastatic non-small cell lung cancer (mNSCLC) patients. We carried out a retrospective analysis aimed to evaluate the antitumor effects of this treatment in a subset of patients with squamous histology...
September 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29199656/retrospective-analysis-of-palliative-metronomic-chemotherapy-in-head-and-neck-cancer
#6
V M Patil, V Noronha, A Joshi, L Nayak, N Pande, A Chandrashekharan, S Dhumal, A Bhattacharjee, S Banavali, K Prabhash
BACKGROUND: Metronomic chemotherapy has shown promising results in selected patients of head and neck cancer in a small randomized study. This retrospective analysis was done to see whether the efficacy of metronomic chemotherapy in an unselected cohort of head and neck cancer patients is similar to that reported in the randomized study and the influence of the site and subsite of head and neck cancer on survival. MATERIALS AND METHODS: This was a retrospective analysis of head and neck cancer patients who received palliative metronomic chemotherapy between January 2013 and February 2015...
January 2017: Indian Journal of Cancer
https://www.readbyqxmd.com/read/29199655/comparison-of-paclitaxel-cetuximab-chemotherapy-versus-metronomic-chemotherapy-consisting-of-methotrexate-and-celecoxib-as-palliative-chemotherapy-in-head-and-neck-cancers
#7
V M Patil, V Noronha, A Joshi, V Agarwala, V Muddu, A Ramaswamy, A Chandrasekharan, S Dhumal, S Juvekar, A Arya, A Bhattacharjee, K Prabhash
BACKGROUND: The present match pair analysis was planned to compare the efficacy of cetuximab-paclitaxel-based chemotherapy versus metronomic therapy. MATERIALS AND METHODS: Sixty patients with metastatic/recurrent head and neck squamous cell cancer treated with weekly paclitaxel (80 mg/m2) and cetuximab were matched with sixty patients treated with oral metronomic chemotherapy consisting of methotrexate and celecoxib. The progression-free survival (PFS) and overall survival (OS) between the cohorts were compared using log-rank test...
January 2017: Indian Journal of Cancer
https://www.readbyqxmd.com/read/29167002/-efficacy-and-toxicity-of-metronomic-oral-vinorelbinen-in-advanced-non-small-cell-lung-cancer-after-failure-to-multiple-lines-treatments
#8
Shuyang Yao, Yanfei Gu, Yi Zhang
BACKGROUND: The development of new treatments beyond first-line in metastatic non-small cell lung cancer (NSCLC) contributed to the increase in overall survival. Metronomic chemotherapy involves several mechanisms of anti-tumor with less toxicity. Oral vinorelbine has paved the way for innovative treatment strategies through metronomic regimens. Therefore, this study assessed the efficacy and safety of metronomic oral vinorelbinen in advanced NSCLC after failure to multiple-lines treatments...
November 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/29163773/tumor-response-of-temozolomide-in-combination-with-morphine-in-a-xenograft-model-of-human-glioblastoma
#9
Anna Lisa Iorio, Martina da Ros, Lorenzo Genitori, Maurizio Lucchesi, Fabiana Colelli, Giacomo Signorino, Francesco Cardile, Giacomo Laffi, Maurizio de Martino, Claudio Pisano, Iacopo Sardi
Despite multimodal treatments comprising, radiation therapy (RT) and chemotherapy with temozolomide (TMZ), the prognosis of glioblastoma multiforme (GBM) remains dismal and consolidated therapy yields a median survival of 14.6 months. Blood Brain Barrier (BBB) mediated chemoresistance and high dose related toxicity make necessary the development of new therapeutic approach to sensitize GBM to TMZ. The aim of the present study was to investigate the potential of the treatment morphine plus TMZ metronmic doses (1,77 and 0,9 mg/kg) in GBM therapy...
October 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/29163174/sustained-complete-response-to-metronomic-chemotherapy-in-a-child-with-refractory-atypical-teratoid-rhabdoid-tumor-a-case-report
#10
Mahe Berland, Laetitia Padovani, Angélique Rome, Grégoire Pech-Gourg, Dominique Figarella-Branger, Nicolas André
Atypical teratoid rhabdoid tumor (ATRT) is a rare and highly aggressive embryonal tumor of the central nervous system with a dismal prognosis and no definitive guidelines for treatment, especially at relapse or in case of refractory disease. Metronomic chemotherapy (MC) has emerged as a new treatment option in solid malignancies, with lower toxicity and is frequently combined with drug repositioning. We report a case of ATRT in an 8-year-old boy who progressed during multimodal therapy including surgical resection, chemotherapy and radiotherapy...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29148865/metronomic-therapy-has-low-toxicity-and-is-as-effective-as-current-standard-treatment-for-recurrent-high-risk-neuroblastoma
#11
Frank Berthold, Marc Hömberg, Inna Proleskovskaya, Pavel Mazanek, Margarita Belogurova, Angela Ernst, Jaroslav Sterba
The metronomic therapy concept uses low doses of continuously applied chemotherapeutic, anti-angiogenetic, and immunomodulating drugs. Twenty patients with recurrent and 3 with refractory high-risk neuroblastoma were treated by the metronomic concept using celecoxib, cyclophosphamide, vinblastine, and etoposide for up to 24 months. The outcome was compared to 274 matched patients with a first recurrence from stage 4 neuroblastoma using the variables time from diagnosis to first recurrence, number of organs involved, and MYCN amplification...
November 17, 2017: Pediatric Hematology and Oncology
https://www.readbyqxmd.com/read/29108332/whether-low-dose-metronomic-oral-cyclophosphamide-improves-the-response-to-docetaxel-in-first-line-treatment-of-non-triple-negative-metastatic-breast-cancer
#12
Jian Zhang, Leiping Wang, Zhonghua Wang, Biyun Wang, Jun Cao, Fangfang Lv, Sheng Zhang, Zhimin Shao, Xichun Hu
Oral metronomic chemotherapy may target tumor cells indirectly via antiangiogenic activity, restoration of anticancer immune response, or induction of tumor dormancy. We initiated the single-center, randomized, open-label, phase II study to determine whether the addition of metronomic cyclophosphamide to docetaxel (T) (w/o trastuzumab) improves overall response rate (ORR) as first-line treatment among patients with non-triple-negative metastatic breast cancer (MBC). Eligible patients with previously untreated non-triple-negative MBC were randomly assigned (1:1) to receive 3-weekly cycles of Metro-TC (T 75mg/m(2), d1 plus oral cyclophosphamide 50 mg daily) or T alone...
October 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29100279/radiotherapy-prolongs-the-survival-of-advanced-non-small-cell-lung-cancer-patients-undergone-to-an-immune-modulating-treatment-with-dose-fractioned-cisplatin-and-metronomic-etoposide-and-bevacizumab-mpebev
#13
Pierpaolo Pastina, Valerio Nardone, Cirino Botta, Stefania Croci, Paolo Tini, Giuseppe Battaglia, Veronica Ricci, Maria Grazia Cusi, Claudia Gandolfo, Gabriella Misso, Silvia Zappavigna, Michele Caraglia, Antonio Giordano, Donatella Aldinucci, Pierfrancesco Tassone, Pierosandro Tagliaferri, Luigi Pirtoli, Pierpaolo Correale
Radiotherapy (RT), together with a direct cytolytic effect on tumor tissue, also elicits systemic immunological events, which sometimes result in the regression of distant metastases (abscopal effect). We have shown the safety and anti-tumor activity of a novel metronomic chemotherapy (mCH) regimen with dose-fractioned cisplatin, oral etoposide and bevacizumab, a mAb against the vasculo-endothelial-growth-factor (mPEBev regimen), in metastatic non-small-cell-lung cancer (mNSCLC). This regimen, designed on the results of translational studies, showed immune-modulating effects that could trigger and empower the immunological effects associated with tumor irradiation...
September 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/29098441/communicative-reprogramming-non-curative-hepatocellular-carcinoma-with-low-dose-metronomic-chemotherapy-cox-2-inhibitor-and-ppar-gamma-agonist-a-phase-ii-trial
#14
I Walter, U Schulz, M Vogelhuber, K Wiedmann, E Endlicher, F Klebl, R Andreesen, W Herr, L Ghibelli, C Hackl, R Wiest, A Reichle
Systemic therapy for advanced hepatocellular carcinoma (HCC) is still challenging. A biomodulatory therapy approach targeting the communicative infrastructure of HCC, including metronomic low-dose chemotherapy with capecitabine, pioglitazone and rofecoxib, has been evaluated in patients with non-curative HCC. Altogether 38 patients were evaluable in this one-arm, multicenter phase II trial. The primary endpoint, median progression-free survival was 2.7 months (95% CI: 1.6-3.79) for all evaluable patients and 8...
November 2, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29029389/a-ketogenic-diet-supplemented-with-medium-chain-triglycerides-enhances-the-anti-tumor-and-anti-angiogenic-efficacy-of-chemotherapy-on-neuroblastoma-xenografts-in-a-cd1-nu-mouse-model
#15
Sepideh Aminzadeh-Gohari, René Günther Feichtinger, Silvia Vidali, Felix Locker, Tricia Rutherford, Maura O'Donnel, Andrea Stöger-Kleiber, Johannes Adalbert Mayr, Wolfgang Sperl, Barbara Kofler
Neuroblastoma (NB) is a pediatric malignancy characterized by a marked reduction in aerobic energy metabolism. Recent preclinical data indicate that targeting this metabolic phenotype by a ketogenic diet (KD), especially in combination with calorie restriction, slows tumor growth and enhances metronomic cyclophosphamide (CP) therapy of NB xenografts. Because calorie restriction would be contraindicated in most cancer patients, the aim of the present study was to optimize the KD such that the tumors are sensitized to CP without the need of calorie restriction...
September 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29027915/a-combination-of-immune-checkpoint-inhibition-with-metronomic-chemotherapy-as-a-way-of-targeting-therapy-resistant-cancer-cells
#16
REVIEW
Irina Kareva
Therapeutic resistance remains a major obstacle in treating many cancers, particularly in advanced stages. It is likely that cytotoxic lymphocytes (CTLs) have the potential to eliminate therapy-resistant cancer cells. However, their effectiveness may be limited either by the immunosuppressive tumor microenvironment, or by immune cell death induced by cytotoxic treatments. High-frequency low-dose (also known as metronomic) chemotherapy can help improve the activity of CTLs by providing sufficient stimulation for cytotoxic immune cells without excessive depletion...
October 13, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29024988/low-dose-metronomic-delivery-of-cyclophosphamide-is-less-detrimental-to-granulosa-cell-viability-ovarian-function-and-fertility-than-maximum-tolerated-dose-delivery-in-the-mouse
#17
Jacqueline Dynes, Kata Osz, Allyssa Hooper, Jim Petrik
Chemotherapy can cause early menopause or infertility in women and have a profound negative impact on the quality of life of young female cancer survivors. Various factors are known to influence the risk of chemotherapy-induced ovarian failure, including the drug dose and treatment duration; however, the scheduling of dose administration has not yet been evaluated as an independent risk factor. We hypothesized that low-dose metronomic (LDM) chemotherapy scheduling would be less detrimental to ovarian function than the traditional maximum tolerated dose (MTD) strategy...
September 1, 2017: Biology of Reproduction
https://www.readbyqxmd.com/read/28986381/chemotherapeutic-dose-scheduling-based-on-tumor-growth-rates-provide-a-case-for-low-dose-metronomic-high-entropy-therapies
#18
Jeffrey B West, Paul K Newton
We extended the classical tumor regression models such as Skipper's laws and the Norton-Simon hypothesis from instantaneous regression rates to the cumulative effect over repeated cycles of chemotherapy. To achieve this end, we used a stochastic Moran process model of tumor cell kinetics coupled with a prisoner's dilemma game-theoretic cell-cell interaction model to design chemotherapeutic strategies tailored to different tumor growth characteristics. Using the Shannon entropy as a novel tool to quantify the success of dosing strategies, we contrasted maximum tolerated dose (MTD) strategies as compared with low-dose, high-density metronomic strategies (LDM) for tumors with different growth rates...
October 6, 2017: Cancer Research
https://www.readbyqxmd.com/read/28900339/metastatic-primary-angiosarcoma-of-the-breast-can-we-tame-it-the-metronomic-way
#19
Raja Pramanik, Ajay Gogia, Prabhat Singh Malik, Ramana Gogi
Primary angiosarcoma of the breast is a highly aggressive but rare malignant neoplasm. Palliative chemotherapy with different agents and combinations has been tried in the metastatic setting with poor results. We present the case of a young woman with this disease describing her aggressive course. We used a metronomic combination of oral drugs due to her poor general condition and achieved disease stabilization although not durable.
April 2017: Indian Journal of Medical and Paediatric Oncology
https://www.readbyqxmd.com/read/28892429/adjuvant-doxorubicin-with-or-without-metronomic-cyclophosphamide-for-canine-splenic-hemangiosarcoma
#20
Arata Matsuyama, Valerie J Poirier, Fernanda Mantovani, Robert A Foster, Anthony J Mutsaers
This retrospective study investigated the outcome of 33 dogs with splenic hemangiosarcoma treated with surgery followed by adjuvant dose-intensified doxorubicin (DOX) with or without low-dose metronomic cyclophosphamide (LDM-C) maintenance therapy. Among the 33 dogs, 18 dogs received LDM-C. Clinical stage was available for all dogs (5 stage I, 18 stage II, and 10 stage III). Nine dogs had macroscopic, and 24 dogs had microscopic disease at the start of DOX treatment. Median progression-free survival (PFS) and overall survival were 125 and 133 days, respectively...
September 11, 2017: Journal of the American Animal Hospital Association
keyword
keyword
33012
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"